When Is the Right Time to Consider Anti‑Aging Therapies?

Estimated read time: ~5 min

Summary:

• Aging pathways seem to help early and harm later — systems that drive growth and resilience in youth can fuel disease with age.
• Timing may matter more than the drug — starting too early may backfire; most therapies make the most theoretical sense in midlife or later.
• Personal biology and unique longevity goals come first — shared decision making about unproven gerotherapeutics should be individualized, not based on age alone.

Modern medicine has become very good at treating disease once it appears. But a growing field that studies aging biology, geroscience, and the associated field of medicine that hopes to translate it to the clinic, geromedicine, asks a different question: What if we could slow the biological processes that cause many chronic diseases in the first place?

This idea has fueled interest in so‑called gerotherapeutics: medications and interventions that target the biology of aging itself. Examples of potential gerotherapeutics (nothing is proven in humans yet) include drugs like metformin, rapamycin, GLP‑1 receptor agonists, and SGLT2 inhibitors—many of which were originally developed for diabetes, cancer, or immune conditions.

But an important and often overlooked question remains: If shared decision making with my healthspan physician concludes a gerotherapeutic trial is reasonable, when is the right time to consider these experimental therapies? The answer is not “as early as possible.” In fact, starting too early may do more harm than good. To understand why, we need to look at how aging works from an evolutionary and biological perspective.

Aging is often described as the gradual accumulation of damage. While that’s partly true, it’s not the full story. A powerful concept called antagonistic pleiotropy (and yes it’s important to understand what this is because it tells us about the timing of gerotherapeutic initiation) helps explain why aging happens at all. First proposed by evolutionary biologist George Williams, the theory suggests that many biological pathways are beneficial early in life—supporting growth, reproduction, and resilience—but become harmful later on when they remain active beyond their useful window.¹

In other words, some of the same systems that help us thrive in youth quietly drive aging and disease decades later. Large genetic studies in humans support this idea. Variants associated with higher fertility and reproductive success are also linked to shorter lifespan and higher risk of age‑related disease.² Natural selection strongly favors early‑life success, even if it comes at a cost later. This framework matters because many proposed anti‑aging therapies target exactly these pathways. And stunting growth and reproduction too early in one’s life by taking an experimental anti-aging therapy may actually decrease your longevity.

Several biological systems illustrate antagonistic pleiotropy particularly well:

The mTOR pathway is essential for development. Without it, life cannot begin. But when mTOR remains highly active in adulthood, it promotes excessive cellular growth, suppresses cellular cleanup (autophagy), and contributes to cancer, cardiovascular disease, and neurodegeneration.³ Some researchers describe aging as a state of biological overdrive—growth programs that never fully shut off.⁴

Insulin and IGF‑1 help regulate metabolism and tissue repair early in life. Chronically elevated signaling later on, however, is linked to insulin resistance, cancer risk, and mitochondrial dysfunction.⁵

Senescent cells stop dividing to prevent cancer—a good thing in youth. But over time, they accumulate and release inflammatory signals that damage surrounding tissue, contributing to frailty and chronic disease.⁶

These systems are not “bad.” They are essential. The problem arises when they remain dominant long after their original purpose has passed.

Because these pathways are beneficial early and harmful later, the timing of intervention is critical. Suppressing growth pathways too early may impair immune function, wound healing, fertility, or muscle maintenance. Waiting too long, on the other hand, may limit benefit once damage is advanced. This is why gerotherapeutics are best viewed not as anti‑aging shortcuts, but as tools to be considered at specific life stages, based on biology—not birthdays alone.

Rapamycin directly inhibits mTOR. In animal studies, it reliably extends lifespan—even when started later in life.⁷ Importantly, early‑life mTOR inhibition can be harmful, while later‑life inhibition appears protective.

In humans, low‑dose or intermittent rapamycin has improved immune responses in older adults without causing significant immunosuppression.⁸ However, long‑term data in healthy individuals are still limited.

Best considered: Midlife or later (often after age 50), when growth signaling has become excessive rather than beneficial.

Metformin activates AMPK, reduces inflammation, and indirectly dampens mTOR signaling. It has decades of safety data and is widely used for diabetes prevention.

Interestingly, metformin appears most effective in younger adults with metabolic risk, such as those with obesity or a history of gestational diabetes.⁹ Its benefits diminish in lean, metabolically healthy older adults.

A large trial (TAME) is underway to test whether metformin can delay multiple age‑related diseases simultaneously.¹⁰

Best considered:

• Earlier in life for people with insulin resistance
• Midlife for gerotherapeutic effect
• Used cautiously in frail older adults

GLP‑1 medications improve insulin sensitivity, reduce inflammation, and have strong cardiovascular benefits. Emerging research suggests they may counteract age‑related molecular changes—particularly in older organisms.¹¹

Interestingly, cardiovascular benefits appear greater in younger adults, while older adults may experience more side effects such as muscle loss or excessive weight loss.¹²

Best considered: Midlife, especially when metabolic or cardiovascular risk begins to rise.

SGLT2 inhibitors promote glucose excretion, shift metabolism toward fat use, and activate longevity‑associated pathways like AMPK and SIRT1.¹³

Unlike GLP‑1 drugs, their cardiovascular benefits appear stronger in older adults, even when blood sugar changes are modest.¹²

Best considered: Midlife or later, particularly in individuals with cardiovascular or kidney risk.

There is no single test that tells us when aging pathways turn from helpful to harmful. But patterns emerge. Rising inflammatory markers (such as CRP or IL‑6), worsening insulin sensitivity, declining muscle strength, slower walking speed, and subtle cognitive changes often signal a biological shift.¹⁴ Some hormones, like IGF‑1, appear beneficial early in life but harmful when chronically elevated later—a phenomenon known as “role‑switching.”¹⁵ Clinically, changes in function often matter more than lab values alone.

Age alone is not enough to guide decisions, especially in the grey-area of geromedicine due to the need for more research. Genetics, sex, lifestyle, kidney function, muscle mass, and personal goals all influence risk and benefit—all factors that must be discussed with a non-biased healthspan medicine physician who knows you well.

For example:

• Women may experience stronger effects—and more side effects—from certain therapies
• Kidney disease alters medication safety
• Regular exercise may delay the need for pharmacologic intervention

This is why shared decision‑making is central to responsible gerotherapeutic use.¹⁶

There is understandable excitement around anti‑aging medicine (geromedicine). But biology does not reward impatience.

The best evidence today supports a measured approach:

• Focus first on lifestyle foundations (these return the highest known yield)
• Monitor biological signals of aging (not the DTC tests, but everything else)
• Introduce therapies when pathways shift from adaptive to harmful (discuss with your provider when you think this may be)
• Reassess regularly as health and priorities evolve

1. Gems D, Kern CC. Ageing Res Rev. 2024;101:102527.
2. Long E, Zhang J. Sci Adv. 2023;9(49):eadh4990.
3. Blagosklonny MV. Cell Cycle. 2010;9(16):3151‑3156.
4. Gems D. Ageing Res Rev. 2022;74:101557.
5. Stern M. Aging Cell. 2017;16(3):435‑443.
6. Thoppil H, Riabowol K. Front Cell Dev Biol. 2019;7:367.
7. Zhang Y, et al. Ageing Res Rev. 2021;70:101376.
8. Forman DE, et al. J Am Coll Cardiol. 2023;82(7):631‑647.
9. American Diabetes Association. Diabetes Care. 2026;49(Suppl 1):S50‑S60.
10. Espinoza SE, et al. J Gerontol A Biol Sci Med Sci. 2023;78(Suppl 1):53‑60.
11. Huang J, et al. Cell Metab. 2025.
12. Hanlon P, et al. JAMA. 2025;333(12):1062‑1073.
13. Hoong CWS, Chua MWJ. Endocrinology. 2021;162(8):bqab079.
14. Cummings SR, Kritchevsky SB. GeroScience. 2022;44(6):2925‑2931.
15. Moeller M, et al. Aging Cell. 2014;13(4):729‑738.
16. Dennison Himmelfarb CR, et al. Circulation. 2023;148(11):912‑931.